Description
IL-6 Monoclonal Antibody
| Catalog number: | B2015284 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 10 g |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Powder |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | IL-6 Monoclonal antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) Immunotherapy Cold Spring Harb Perspect Biol. 2018 Aug 1;10(8):a028456.
- Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295.
- Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors Bioorg Med Chem. 2020 Mar 1;28(5):115327.
- Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra) Hum Vaccin Immunother. 2017 Sep 2;13(9):1972-1988.
- Pandolfi F, Franza L, Carusi V, Altamura S, Andriollo G, Nucera E. Interleukin-6 in Rheumatoid Arthritis Int J Mol Sci. 2020 Jul 23;21(15):5238.
- Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mhlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Bhmig GA. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection J Am Soc Nephrol. 2021 Mar;32(3):708-722.
- Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, Azizi G. Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach Int Immunopharmacol. 2022 Oct;111:109130.
- McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness Lancet Respir Med. 2021 Jun;9(6):643-654.
- Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, Samsonov M, Smolen JS, Fleischmann RM. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study Ann Rheum Dis. 2022 Dec;81(12):1661-1668.
